Zebra Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Zebra Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,975	Closed	-$148K	–	89
2022 Q3	$148K	Buy	14,975 +209	+1%	+$2.21K	0.56%	62
2022 Q2	$161K	Sell	14,766 -335	-2%	-$3.47K	0.47%	79
2022 Q1	$171K	Sell	15,101 -4,258	-22%	-$56K	0.39%	99
2021 Q4	$304K	Sell	19,359 -3,519	-15%	-$61.3K	0.49%	68
2021 Q3	$392K	Sell	22,878 -7,008	-23%	-$123K	0.47%	71
2021 Q2	$642K	Sell	29,886 -2,073	-6%	-$37.1K	0.75%	45
2021 Q1	$480K	Buy	+31,959	New	+$517K	0.53%	72
2019 Q4	–	Sell	-15,634	Closed	-$208K	–	320
2019 Q3	$208K	Buy	15,634 +3,582	+30%	+$49.9K	0.23%	181
2019 Q2	$170K	Buy	+12,052	New	+$192K	0.09%	417

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Zebra Capital Management's VNDA Position: Q4 2022 in Review

Zebra Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2022, closing a stake of 14,975 shares — an estimated $148K sold.

Zebra Capital Management first reported a position in VNDA in Q2 2019 and held it in 9 quarters. The position peaked at $642K in Q2 2021. 190 funds tracked by Wall St. Rank hold VNDA as of Q4 2022.

Zebra Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Zebra Capital Management sold 14,975 Vanda Pharmaceuticals shares in Q4 2022, an estimated $148K.
Zebra Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 9 quarters.
Zebra Capital Management's Vanda Pharmaceuticals position peaked at $642K in Q2 2021.
190 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2022.

Based on Zebra Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.